Tomivosertib
Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines[1]. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance[2].
Product Specifications
CAS Number
1849590-01-7
Product Name Alternative
EFT508
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
MNK; PD-1/PD-L1
Type
Reference compound
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/eFT508.html
Purity
99.92
Solubility
DMSO : 8 mg/mL (ultrasonic)
Smiles
O=C(C1=C(C)C=C(NC2=NC=NC(N)=C2)C(N13)=O)NC43CCCCC4
Molecular Formula
C17H20N6O2
Molecular Weight
340.38
Precautions
H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
MNK1; MNK2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
